Shares in Thermo Fisher Scientific show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed. Investors have an opportunity to buy the stock and target the $ 530.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
The company returns high margins, thereby supporting business profitability.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
For several months, analysts have been revising their EPS estimates roughly upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 354.2 USD
Stock prices approach a strong long-term resistance in weekly data at USD 516.58.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company benefits from high valuations in earnings multiples.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.